Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLT NYSE:AMPX NASDAQ:AVAV NASDAQ:CMPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLTAllot$9.79-1.5%$8.32$2.78▼$10.77$462.52M1.43518,921 shs340,300 shsAMPXAmprius Technologies$10.66-2.5%$8.21$0.97▼$12.29$1.37B2.728.76 million shs6.68 million shsAVAVAeroVironment$308.69+2.5%$258.00$102.25▼$317.11$15.04B1.031.21 million shs1.44 million shsCMPXCompass Therapeutics$3.82+2.1%$3.25$1.27▼$4.08$517.18M1.51.28 million shs1.08 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLTAllot0.00%+1.12%+26.46%+16.26%+234.68%AMPXAmprius Technologies0.00%-6.94%+54.72%+158.54%+887.57%AVAVAeroVironment0.00%+8.13%+24.80%+5.70%+51.18%CMPXCompass Therapeutics0.00%+10.32%+7.16%+43.85%+98.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLTAllot$9.79-1.5%$8.32$2.78▼$10.77$462.52M1.43518,921 shs340,300 shsAMPXAmprius Technologies$10.66-2.5%$8.21$0.97▼$12.29$1.37B2.728.76 million shs6.68 million shsAVAVAeroVironment$308.69+2.5%$258.00$102.25▼$317.11$15.04B1.031.21 million shs1.44 million shsCMPXCompass Therapeutics$3.82+2.1%$3.25$1.27▼$4.08$517.18M1.51.28 million shs1.08 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLTAllot0.00%+1.12%+26.46%+16.26%+234.68%AMPXAmprius Technologies0.00%-6.94%+54.72%+158.54%+887.57%AVAVAeroVironment0.00%+8.13%+24.80%+5.70%+51.18%CMPXCompass Therapeutics0.00%+10.32%+7.16%+43.85%+98.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLTAllot 2.50Moderate BuyN/AN/AAMPXAmprius Technologies 3.11Buy$11.719.91% UpsideAVAVAeroVironment 3.05Buy$304.69-1.30% DownsideCMPXCompass Therapeutics 3.11Buy$13.88263.22% UpsideCurrent Analyst Ratings BreakdownLatest CMPX, AVAV, ALLT, and AMPX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/29/2025AVAVAeroVironmentRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$300.00 ➝ $348.009/25/2025ALLTAllotZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/25/2025AVAVAeroVironmentRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$300.00 ➝ $330.009/23/2025AVAVAeroVironmentZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/19/2025AVAVAeroVironmentBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$300.009/18/2025AVAVAeroVironmentBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$300.009/16/2025AVAVAeroVironmentWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform9/11/2025AVAVAeroVironmentBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$300.009/10/2025AVAVAeroVironmentNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$300.009/9/2025AVAVAeroVironmentRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$300.008/27/2025ALLTAllotZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 9/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLTAllot$92.19M4.94$0.05 per share210.30$1.30 per share7.53AMPXAmprius Technologies$24.17M55.16N/AN/A$0.59 per share18.06AVAVAeroVironment$820.63M18.78$5.54 per share55.68$31.36 per share9.84CMPXCompass TherapeuticsN/AN/AN/AN/A$0.91 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLTAllot-$5.87M-$0.05N/AN/AN/A-2.12%0.94%0.40%11/18/2025 (Estimated)AMPXAmprius Technologies-$44.67M-$0.33N/AN/AN/A-84.77%-55.79%-32.57%11/6/2025 (Estimated)AVAVAeroVironment$43.62M-$0.64N/A69.375.11-4.14%4.67%3.73%12/3/2025 (Estimated)CMPXCompass Therapeutics-$49.38M-$0.45N/AN/AN/AN/A-53.11%-46.14%11/11/2025 (Estimated)Latest CMPX, AVAV, ALLT, and AMPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/9/2025Q1 2026AVAVAeroVironment$0.34$0.32-$0.02-$1.44$446.16 million$454.68 million8/14/2025Q2 2025ALLTAllot-$0.02-$0.01+$0.01-$0.04$22.90 million$24.05 million8/11/2025Q2 2025CMPXCompass Therapeutics-$0.13-$0.14-$0.01-$0.14N/AN/A8/7/2025Q2 2025AMPXAmprius Technologies-$0.08-$0.05+$0.03-$0.05$12.38 million$15.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLTAllotN/AN/AN/AN/AN/AAMPXAmprius TechnologiesN/AN/AN/AN/AN/AAVAVAeroVironmentN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLTAllotN/A2.091.88AMPXAmprius TechnologiesN/A5.955.59AVAVAeroVironment0.165.965.12CMPXCompass TherapeuticsN/A7.667.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLTAllot51.50%AMPXAmprius Technologies5.04%AVAVAeroVironment86.38%CMPXCompass Therapeutics68.43%Insider OwnershipCompanyInsider OwnershipALLTAllot3.40%AMPXAmprius Technologies12.80%AVAVAeroVironment0.81%CMPXCompass Therapeutics29.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLTAllot74046.53 million44.95 millionOptionableAMPXAmprius Technologies50125.08 million109.07 millionOptionableAVAVAeroVironment1,47549.93 million49.53 millionOptionableCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableCMPX, AVAV, ALLT, and AMPX HeadlinesRecent News About These CompaniesGoldman Sachs Group Inc. Sells 156,917 Shares of Compass Therapeutics, Inc. $CMPXSeptember 27 at 4:55 AM | marketbeat.comAnalysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Target Price at $13.88September 27 at 2:49 AM | americanbankingnews.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Rating of "Buy" by BrokeragesSeptember 24, 2025 | marketbeat.comGuggenheim Sees Compass (CMPX) Potential Driven by Biliary Tract Cancer PipelineSeptember 11, 2025 | finance.yahoo.comCompass Therapeutics, Inc. (CMPX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comAdage Capital Partners GP L.L.C. Cuts Stock Position in Compass Therapeutics, Inc. $CMPXSeptember 9, 2025 | marketbeat.comAmerican Century Companies Inc. Takes $140,000 Position in Compass Therapeutics, Inc. $CMPXSeptember 9, 2025 | marketbeat.com304,504 Shares in Compass Therapeutics, Inc. $CMPX Purchased by Nuveen LLCSeptember 6, 2025 | marketbeat.comMPM Bioimpact LLC Trims Stock Position in Compass Therapeutics, Inc. $CMPXSeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Cuts Stake in Compass Therapeutics, Inc. $CMPXSeptember 4, 2025 | marketbeat.com222,505 Shares in Compass Therapeutics, Inc. $CMPX Bought by Wellington Management Group LLPSeptember 3, 2025 | marketbeat.comPropel Bio Management LLC Acquires New Position in Compass Therapeutics, Inc. $CMPXSeptember 2, 2025 | marketbeat.comPiper Sandler Reaffirms Optimism on Compass Therapeutics (CMPX) Amid Trial UpdateSeptember 2, 2025 | finance.yahoo.comDeutsche Bank AG Purchases Shares of 102,041 Compass Therapeutics, Inc. $CMPXSeptember 1, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Recommendation of "Buy" from AnalystsSeptember 1, 2025 | marketbeat.comCompass Therapeutics to Participate in Upcoming September Investor EventsAugust 26, 2025 | globenewswire.comCompass Therapeutics (CMPX) Rated ‘Outperform’ amid Clinical Pipeline DevelopmentAugust 19, 2025 | insidermonkey.comCompass Therapeutics Announces Public Offering to Raise $112.5MAugust 14, 2025 | msn.comCompass Therapeutics 33.3M share Spot Secondary priced at $3.00August 13, 2025 | msn.comCompass Therapeutics Announces Pricing of Upsized $120 Million Public OfferingAugust 12, 2025 | globenewswire.comCompass Therapeutics price target raised to $12 from $10 at GuggenheimAugust 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Oracle Has Spoken: AI Changes EverythingBy Thomas Hughes | September 10, 20253 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025AeroVironment Is a Hot Buy With a Double-Digit UpsideBy Thomas Hughes | September 11, 2025Amprius Technologies: Anatomy of a Textbook, Raging Bull MarketBy Thomas Hughes | September 23, 2025CMPX, AVAV, ALLT, and AMPX Company DescriptionsAllot NASDAQ:ALLT$9.79 -0.15 (-1.51%) Closing price 04:00 PM EasternExtended Trading$9.78 -0.01 (-0.10%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allot Communications Ltd. is a provider of leading innovative network intelligence and security solutions for service providers worldwide, enhancing value to their customers. Their solutions are deployed globally for network and application analytics, traffic control and shaping, network-based security services, and more. Allot's multi-service platforms are deployed by over 500 mobile, fixed and cloud service providers and over 1000 enterprises. Their industry leading network-based security as a service solution has achieved over 50% penetration with some service providers and is already used by over 20 million subscribers in Europe.Amprius Technologies NYSE:AMPX$10.66 -0.27 (-2.49%) Closing price 03:59 PM EasternExtended Trading$10.62 -0.03 (-0.31%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amprius Technologies, Inc. produces and sells ultra-high energy density lithium-ion batteries for mobility applications. The company offers silicon nanowire anode batteries. Its batteries are primarily used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. The company was incorporated in 2008 and is headquartered in Fremont, California.AeroVironment NASDAQ:AVAV$308.69 +7.49 (+2.49%) Closing price 04:00 PM EasternExtended Trading$309.00 +0.31 (+0.10%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AeroVironment, Inc. designs, develops, produces, delivers, and supports a portfolio of robotic systems and related services for government agencies and businesses in the United States and internationally. It operates through Small Unmanned Aircraft Systems (SUAS), Tactical Missile System (TMS), Medium Unmanned Aircraft Systems (MUAS), and High Altitude Pseudo-Satellite Systems (HAPS) segments. The company supplies UAS, TMS, unmanned ground vehicle, and related services primarily to organizations within the U.S. Department of Defense, other federal agencies, and to international allied governments. It also designs, engineers, tools, and manufactures unmanned aerial and aircraft systems, including airborne platforms, payloads and payload integration, ground control systems, and ground support equipment and other items and services related to unmanned aircraft systems. In addition, the company offers small UAS products, including training, spare parts, product repair, product replacement, and the customer contracted operation. Further, it develops high-altitude pseudo-satellite UAS systems. AeroVironment, Inc. was incorporated in 1971 and is headquartered in Arlington, Virginia.Compass Therapeutics NASDAQ:CMPX$3.82 +0.08 (+2.14%) Closing price 04:00 PM EasternExtended Trading$3.84 +0.02 (+0.52%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Top-Rated Dividend Growth Stocks to Buy in October Top Insider Buys and Sells From September: Buy, Sell, or Hold? This ETF Weeds Out Small-Cap Underperformers Dividend ETF SCHD Draws Buyers as Fed Cuts Spark Rotation Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300 MarketBeat Week in Review – 09/22 - 09/26 Get Exposure to Millennials' Purchasing Power With This ETF Beam Global Gets Buy Rating With 101% Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
